Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

PURPOSE: We aimed to identify the maximum-tolerated dose (MTD) of irinotecan in patients with cancer with UGT1A1*1/*1 and *1/*28 genotypes. We hypothesize that the patients without the *28/*28 genotype tolerate higher doses of irinotecan. PATIENTS AND METHODS: Patients undergoing first-line treatmen...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Toffoli, Giuseppe, Cecchin, Erika, Gasparini, Giampiero, D'Andrea, Mario, Azzarello, Giuseppe, Basso, Umberto, Mini, Enrico, Pessa, Sergio, De Mattia, Elena, Lo Re, Giovanni, Buonadonna, Angela, Nobili, Stefania, De Paoli, Paolo, Innocenti, Federico
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2010
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872310/
https://ncbi.nlm.nih.gov/pubmed/20038727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.6125
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller